On August 21st, the long-awaited amendments to the Patented Medicines Regulations were published in Part II of the Canada Gazette. We have prepared an unofficial consolidated version of the Regulations incorporating the...more
8/25/2019
/ Amended Regulation ,
Canada ,
Confidential Information ,
Drug Pricing ,
Exemptions ,
IP License ,
Licensees ,
Patented Medicine Prices Review Board (PMPRB) ,
Patented Medicines ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Prescription Drugs ,
Rebates ,
Reporting Requirements ,
Third-Party
Certificate of Supplementary Protection Regime: First Anniversary Update -
September 21, 2018 marked the first anniversary of the certificate of supplementary protection (CSP) regime. CSPs, which provide an additional...more
10/4/2018
/ Canada ,
Certificates of Supplementary Protection (CSPs) ,
Customer-Loyalty Programs ,
FDA Approval ,
Imports ,
Interim Rule ,
Leave to Appeal ,
Medical Devices ,
Patented Medicine Prices Review Board (PMPRB) ,
Pharmacist ,
PMNOC Regulations ,
Prescription Drugs ,
Prohibition Applications ,
Supreme Court of Canada
Federal Court of Appeal Applies Supreme Court’s Utility Test to SPRYCEL Patent -
In its first decision to consider the Supreme Court of Canada’s landmark decision in AstraZeneca Canada Inc v Apotex Inc, 2017 SCC 36...more
On September 7, 2017, the Government of Canada published final pharmaceutical regulations flowing from CETA. According to an Order in Council, the new regulations will be in force on September 21, 2017....more
The government has published the long anticipated draft regulations regarding:
- changes to the Patented Medicines (Notice of Compliance) Regulations [“PMNOC Regulations”], and
- proposed Regulations to implement...more
The following are highlights of developments in Canadian life sciences intellectual property and regulatory law in 2016, updating our 2016 mid-year highlights.
1. Substantive patent law developments -
Utility and...more
1/11/2017
/ Administrative Proceedings ,
Anti-Competitive ,
Apotex ,
Arbitration ,
AstraZeneca ,
Bayer ,
Biologics ,
Biosimilars ,
CADTH ,
Calculation of Damages ,
CETA ,
Competition Authorities ,
Constitutional Challenges ,
Data Protection ,
Double Patent ,
Eli Lilly ,
Generic Drugs ,
Health Canada ,
Leave to Appeal ,
Life Sciences ,
NAFTA ,
New Guidance ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Terms ,
Patented Medicine Prices Review Board (PMPRB) ,
Patents ,
Pfizer ,
Pharmaceutical Patents ,
PMNOC Regulations ,
Supreme Court of Canada ,
Teva Pharmaceuticals ,
Trans-Pacific Partnership ,
Unjust Enrichment ,
Utility Patents